ERCC1 et cancer pulmonaire

Translated title of the contribution: ERCC1 and lung cancer

D. Planchard, K. A. Olaussen, J. C. Soria

    Research output: Contribution to journalShort surveypeer-review

    2 Citations (Scopus)

    Abstract

    ERCC1 plays a critical role in the repair of lesions in DNA induced by cisplatin. It has been demonstrated that, in patients with resected NSCLC, those with ERCC1-negative tumours had greater benefit from adjuvant chemotherapy than patients with ERCC1-positive tumours. On the other hand, patients with ERCC1-positive tumours have a better prognosis. ERCC1 can be evaluated either by the level of protein expression on immunohistochemical analysis or by quantification of its mRNA expression. At present ERCC1 appears to be a promising biomarker for predicting the benefit of cisplatin based chemotherapy and its modulation could allow sensitisation of tumour cells to this drug. Its use in daily clinical practice requires a further stage of prospective validation studies which are already in progress in patients both with completely resected NSCL or metastatic disease.

    Translated title of the contributionERCC1 and lung cancer
    Original languageFrench
    Pages (from-to)387-394
    Number of pages8
    JournalRevue des Maladies Respiratoires
    Volume27
    Issue number4
    DOIs
    Publication statusPublished - 1 Jan 2010

    Cite this